In the previous issue of Arthritis Research & Th erapy, Jodon de Villeroché and colleagues [1] assessed lateoutgrowth EPCs in RA and found increased colonyformation capacity of these cells in RA. Furthermore, higher or lower EPC numbers correlated with active disease and disease in remission, respectively. Th ese results seem to be somewhat controversial as a number of other investigators reported defective EPC function in RA and lower EPC numbers in active RA [5, 6] . Th ere has been only one report by the same group, Allanore and colleagues [9] , suggesting that circulating EPC numbers may be higher in RA. Nevertheless, Jodon de Villeroché and colleagues [1] conducted an approach that was signifi cantly diff erent from that of others. Instead of analyzing all EPCs, they diff erentiated two EPC subpopulations, namely EPCs of monocytic versus hemangio blastic origin. Th ese two EPC subsets have recently been described and characterized as early-outgrowth and late-outgrowth EPCs, respectively [1, 10] . Th ere is no clear consensus on the accurate defi nition of EPCs after all [10] . In their study, Jodon de Villeroché and colleagues [1] characterized late-outgrowth EPCs of hemangioblastic origin as Lin − /7-aminoactinomycin D (7AAD) − / CD34 + /CD133 + /VEGFR-2 + cells and the number of these cells was indeed higher in RA patients compared with controls. In addition, the colony-forming capacity of these late-outgrowth EPCs was signifi cantly higher in RA.
Jodon de Villeroché and colleagues [1] claim that, in all previous studies, EPCs also consisted of the earlyoutgrowth monocyte-derived cells characterized by only three surface markers (CD34/CD133/VEGF-R2) [5, 6] . According to Jodon de Villeroché and colleagues [1] , the use of Lin and 7AAD markers may enable investigators to select only late-outgrowth EPCs.
Th us, while there may be a general impairment of EPC function and vasculogenesis in RA and low EPC numbers may be associated with RA activity and increased cardiovascular risk, late-outgrowth EPCs of solely heman gioblastic origin may be involved in vascular repair. As this EPC subset may be preferentially involved in the active stage of the disease, it is likely that hemangioblastic EPC-dependent vasculogenesis is more prominent in active RA associated with high-grade systemic infl ammation and accelerated atherosclerosis.
Abstract
Decreased number and impaired functions of endothelial progenitor cells (EPCs) leading to impaired vasculogenesis have been associated with rheumatoid arthritis (RA). Defective vasculogenesis has also been implicated in premature atherosclerosis in RA. Recently, early-outgrowth monocytic and late-outgrowth hemangioblastic EPC subsets have been characterized. Hemangioblastic EPCs may exert increased numbers in active RA and may play a role in vascular repair underlying RA.
